{"id":42406,"date":"2025-09-28T11:40:33","date_gmt":"2025-09-28T03:40:33","guid":{"rendered":"https:\/\/flcube.com\/?p=42406"},"modified":"2025-09-28T11:40:34","modified_gmt":"2025-09-28T03:40:34","slug":"cms-announces-phase-3-success-of-ruxolitinib-cream-in-atopic-dermatitis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=42406","title":{"rendered":"CMS Announces Phase\u202f3 Success of Ruxolitinib Cream in Atopic Dermatitis"},"content":{"rendered":"\n<p><strong>China Medical System Holdings Limited (CMS, <a href=\"https:\/\/www.google.com\/finance\/quote\/0867:HKG\">HKG: 0867<\/a>)<\/strong> reported that its Phase\u202f3, randomized, double\u2011blind, placebo\u2011controlled trial of <strong>ruxolitinib cream<\/strong> (Opzelura) achieved its primary endpoint in patients with mild\u2011to\u2011moderate <strong>atopic dermatitis (AD)<\/strong> across China.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-trial-design-amp-scale\">Trial Design &amp; Scale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sample Size<\/strong>: 192 patients enrolled at multiple centers nationwide.<\/li>\n\n\n\n<li><strong>Comparator<\/strong>: Placebo\u2011controlled, double\u2011blind, with 1:1 randomization.<\/li>\n\n\n\n<li><strong>Primary Endpoint<\/strong>: Proportion achieving <strong>IGA\u202f0\/1<\/strong> with \u2265\u202f2\u2011grade improvement at week\u202f8.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-results\">Key Results<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IGA Success<\/strong>: 63.0\u202f% of ruxolitinib\u2011treated patients vs. 9.2\u202f% of placebo (P\u202f&lt;\u202f0.001).<\/li>\n\n\n\n<li><strong>EASI\u202f75<\/strong>: 78.0\u202f% vs. 15.4\u202f% (P\u202f&lt;\u202f0.001).<\/li>\n\n\n\n<li><strong>Safety<\/strong>: Cream was well\u2011tolerated; adverse events comparable to placebo.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context\">Strategic Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Product Portfolio<\/strong>: Opzelura is the first FDA\u2011approved topical JAK1\/2 inhibitor, currently indicated for non\u2011segmental vitiligo and mild\u2011to\u2011moderate AD in adults and children \u2265\u202f2\u202fyears.<\/li>\n\n\n\n<li><strong>Partnership<\/strong>: CMS holds an exclusive license from <strong>Incyte (<a href=\"https:\/\/www.google.com\/finance\/quote\/INCY:NASDAQ\">NASDAQ: INCY<\/a>)<\/strong> for mainland China, Hong Kong, Macau, Taiwan, and eleven Southeast Asian countries.<\/li>\n\n\n\n<li><strong>Regulatory Milestones<\/strong>: NMPA has accepted the NDA for the vitiligo indication; CMS is actively pursuing the AD indication in China.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-implications\">Market Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Edge<\/strong>: Demonstrated efficacy positions CMS to capture a growing segment of the AD market, potentially displacing conventional topical corticosteroids.<\/li>\n\n\n\n<li><strong>Revenue Outlook<\/strong>: Successful registration of the AD indication could unlock multi\u2011billion\u2011dollar sales in the region, aligning with CMS\u2019s growth strategy in dermatology.<\/li>\n\n\n\n<li><strong>Investor Sentiment<\/strong>: Positive Phase\u202f3 data are likely to bolster analyst coverage and support the stock\u2019s recent rally.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>China Medical System Holdings Limited (CMS, HKG: 0867) reported that its Phase\u202f3, randomized, double\u2011blind, placebo\u2011controlled&#8230;<\/p>\n","protected":false},"author":1,"featured_media":42407,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[325,17,844,999,998],"class_list":["post-42406","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-china-medical-system","tag-clinical-trial-results","tag-hkg-0867","tag-incyte-pharmaceuticals","tag-nasdaq-incy"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CMS Announces Phase\u202f3 Success of Ruxolitinib Cream in Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China Medical System Holdings Limited (CMS, HKG: 0867) reported that its Phase\u202f3, randomized, double\u2011blind, placebo\u2011controlled trial of ruxolitinib cream (Opzelura) achieved its primary endpoint in patients with mild\u2011to\u2011moderate atopic dermatitis (AD) across China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=42406\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CMS Announces Phase\u202f3 Success of Ruxolitinib Cream in Atopic Dermatitis\" \/>\n<meta property=\"og:description\" content=\"China Medical System Holdings Limited (CMS, HKG: 0867) reported that its Phase\u202f3, randomized, double\u2011blind, placebo\u2011controlled trial of ruxolitinib cream (Opzelura) achieved its primary endpoint in patients with mild\u2011to\u2011moderate atopic dermatitis (AD) across China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=42406\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-28T03:40:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-28T03:40:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2807.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"680\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42406#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42406\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CMS Announces Phase\u202f3 Success of Ruxolitinib Cream in Atopic Dermatitis\",\"datePublished\":\"2025-09-28T03:40:33+00:00\",\"dateModified\":\"2025-09-28T03:40:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42406\"},\"wordCount\":242,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42406#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2807.webp\",\"keywords\":[\"China Medical System\",\"Clinical trial results\",\"HKG: 0867\",\"Incyte Pharmaceuticals\",\"NASDAQ: INCY\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42406#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42406\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=42406\",\"name\":\"CMS Announces Phase\u202f3 Success of Ruxolitinib Cream in Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42406#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42406#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2807.webp\",\"datePublished\":\"2025-09-28T03:40:33+00:00\",\"dateModified\":\"2025-09-28T03:40:34+00:00\",\"description\":\"China Medical System Holdings Limited (CMS, HKG: 0867) reported that its Phase\u202f3, randomized, double\u2011blind, placebo\u2011controlled trial of ruxolitinib cream (Opzelura) achieved its primary endpoint in patients with mild\u2011to\u2011moderate atopic dermatitis (AD) across China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42406#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42406\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42406#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2807.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2807.webp\",\"width\":1080,\"height\":680,\"caption\":\"CMS Announces Phase\u202f3 Success of Ruxolitinib Cream in Atopic Dermatitis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42406#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CMS Announces Phase\u202f3 Success of Ruxolitinib Cream in Atopic Dermatitis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CMS Announces Phase\u202f3 Success of Ruxolitinib Cream in Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry","description":"China Medical System Holdings Limited (CMS, HKG: 0867) reported that its Phase\u202f3, randomized, double\u2011blind, placebo\u2011controlled trial of ruxolitinib cream (Opzelura) achieved its primary endpoint in patients with mild\u2011to\u2011moderate atopic dermatitis (AD) across China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=42406","og_locale":"en_US","og_type":"article","og_title":"CMS Announces Phase\u202f3 Success of Ruxolitinib Cream in Atopic Dermatitis","og_description":"China Medical System Holdings Limited (CMS, HKG: 0867) reported that its Phase\u202f3, randomized, double\u2011blind, placebo\u2011controlled trial of ruxolitinib cream (Opzelura) achieved its primary endpoint in patients with mild\u2011to\u2011moderate atopic dermatitis (AD) across China.","og_url":"https:\/\/flcube.com\/?p=42406","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-28T03:40:33+00:00","article_modified_time":"2025-09-28T03:40:34+00:00","og_image":[{"width":1080,"height":680,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2807.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=42406#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=42406"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CMS Announces Phase\u202f3 Success of Ruxolitinib Cream in Atopic Dermatitis","datePublished":"2025-09-28T03:40:33+00:00","dateModified":"2025-09-28T03:40:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=42406"},"wordCount":242,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=42406#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2807.webp","keywords":["China Medical System","Clinical trial results","HKG: 0867","Incyte Pharmaceuticals","NASDAQ: INCY"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=42406#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=42406","url":"https:\/\/flcube.com\/?p=42406","name":"CMS Announces Phase\u202f3 Success of Ruxolitinib Cream in Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=42406#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=42406#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2807.webp","datePublished":"2025-09-28T03:40:33+00:00","dateModified":"2025-09-28T03:40:34+00:00","description":"China Medical System Holdings Limited (CMS, HKG: 0867) reported that its Phase\u202f3, randomized, double\u2011blind, placebo\u2011controlled trial of ruxolitinib cream (Opzelura) achieved its primary endpoint in patients with mild\u2011to\u2011moderate atopic dermatitis (AD) across China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=42406#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=42406"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=42406#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2807.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2807.webp","width":1080,"height":680,"caption":"CMS Announces Phase\u202f3 Success of Ruxolitinib Cream in Atopic Dermatitis"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=42406#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CMS Announces Phase\u202f3 Success of Ruxolitinib Cream in Atopic Dermatitis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2807.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42406","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42406"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42406\/revisions"}],"predecessor-version":[{"id":42408,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42406\/revisions\/42408"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/42407"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42406"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42406"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}